A Retrospective Chart Review of Patients Treated With Ocriplasmin for Symptomatic VMA

Completed

Conditions studied: Symptomatic Vitreomacular Adhesion (VMA)

In brief

The purpose of this study is to retrospectively review and further characterize anatomic and symptomatic changes over six months immediately following treatment of symptomatic vitreomacular adhesion (VMA) with JETREA® (ocriplasmin), including incidence, time to onset and resolution of anatomy and symptoms.

Key facts

Study ID

NCT02193945

Run by

ThromboGenics

People needed

134

Starts

2014-08-01

Expected to finish

2015-05-01

Last updated by the study team

2015-07-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Must be at least 18 years of age or older.
• Have been treated with JETREA® for vitreomacular adhesion (VMA) between April 1, 2013 and December 31, 2013 with at least six months of follow up visits post injection. Note: If a patient's second eye was treated, only the first eye treated is eligible for study participation.
• Have been imaged with Heidelberg Spectralis SD-OCT at least one time within 30 days prior to JETREA® injection.
• Have been imaged with Heidelberg Spectralis SD-OCT at least two times post JETREA® injection with at least one scan between Days 1-21 and the second scan within six months,, including a corresponding visual acuity (VA).
• Be willing and able to provide informed consent.

You may not qualify if…

• Patients treated with JETREA® for medical conditions outside of the product label.
• Patients with other retinal conditions that affect the vitreo-retinal interface, or can lead to retinal atrophy, including but not limited to:
• Neovascular age-related macular degeneration;
• Fibrovascular scar;
• Diabetic macular edema; and
• Proliferative diabetic retinopathy.

Where it is running

• Retinal Diagnostic Center — Campbell, California, United States
• Scripps Clinic — La Jolla, California, United States
• Orange County Retina Medical Group — Santa Ana, California, United States
• California Retina Consultants — Santa Barbara, California, United States
• Retina Vitreous Associates of Florida — St. Petersburg, Florida, United States
• Marietta Eye Clinic — Marietta, Georgia, United States
• Rush university medical center-Dept ophthalmology — Chicago, Illinois, United States
• Carle Foundation Hospital — Urbana, Illinois, United States
• Sabates Eye Centers — Leawood, Kansas, United States
• Carl W. Baker — Paducah, Kentucky, United States
• Ophthalmic Consultants of Boston — Boston, Massachusetts, United States
• Harvard Vanguard Medical Associates — Boston, Massachusetts, United States
• Sierra Eye Associates — Reno, Nevada, United States
• Eyesight Ophthalmic Services — Portsmouth, New Hampshire, United States
• MaculaCare — New York, New York, United States
• Duke University Eye Center — Durham, North Carolina, United States
• Wills Eye Institute — Philadelphia, Pennsylvania, United States
• Black Hills Regional Eye Institute — Rapid City, South Dakota, United States
• Southeastern Retina Associates, P.C. — Kingsport, Tennessee, United States
• Retina Consultants of Houston — Houston, Texas, United States
• Valley Retina Institute, PA — McAllen, Texas, United States
• Retina Specialists — Plano, Texas, United States
• Retina Associates of Utah, P.C. — Salt Lake City, Utah, United States
• West Virginia University Eye Institute — Morgantown, West Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.